Read More Pharma Industry News Schrödinger (NASDAQ: SDGR) trims 2025 software growth forecast to 8%–13% despite strong Q3 results Find out why Schrödinger’s revised software guidance may mark a shift in pharma AI strategy, with delayed deals and a pivot to operational efficiency. byPallavi MadhirajuNovember 6, 2025